The bota-vec reacquisition and $100M financing transform MGTX into a late-stage, multi-asset gene therapy company with two wholly-owned programs approaching regulatory filings. The stock's next major catalyst is the AQUAx2 12-month data in Q2 2027, but near-term attention will focus on regulatory submission timelines for bota-vec in the US, EU, UK, and Japan. Monitor for IND filing for Ribo-Leptin later this year.
Price Chart
Executive Summary
MeiraGTx reported Q1 2026 results with a net loss of $46.3M ($0.57/share) vs $40.0M ($0.51/share) a year ago, while total revenue fell 85% to $0.3M as PPQ services for J&J wound down. The quarter was dominated by strategic catalysts: the reacquisition of bota-vec from J&J for $25M upfront, a $100M equity offering, and FDA Breakthrough Therapy Designation for AAV2-hAQP1. The company's cash runway now extends into H2 2028, de-risking the path to potential BLA filing for AAV2-hAQP1 in H1 2027.
Key Financial Metrics
Key Facts
- Net loss of $46.3M ($0.57/share) for Q1 2026 vs $40.0M ($0.51/share) in Q1 2025
- Total revenue fell to $0.3M from $1.9M as PPQ services for J&J were substantially completed
- Reacquired full rights to bota-vec (XLRP) from J&J for $25M upfront cash
- Completed $100M equity offering (11.1M shares at $9.00/share) in April 2026
- Cash and equivalents of $71.5M at March 31, 2026; runway extended into H2 2028 including $95M due from Hologen
- FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 in March 2026
- Phase 2 AQUAx2 pivotal data readout on track for Q2 2027, with potential BLA filing H1 2027
- Debt obligations of $25M (due June 2026) and $50M (due July 2027) to Perceptive Credit
Financial Impact
Net loss widened by $6.3M YoY to $46.3M; revenue declined 85% due to completion of J&J PPQ services; $100M equity raise and $95M Hologen receivable extend cash runway into H2 2028
Risk Factors
- Dilution from 11.1M share offering at $9.00 (below recent trading levels)
- Clinical trial risk for AAV2-hAQP1 Phase 2 AQUAx2 study
- Execution risk on global regulatory filings for bota-vec
- Shareholders' deficit of $58.1M as of March 31, 2026
- Dependence on Hologen JV funding ($95M remaining) for AAV-GAD development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-060726 |
| Document: mgtx-20260514x8k.htm | 0001104659-26-060726 |
| Document: 0001104659-26-060726-index-headers.html | 0001104659-26-060726 |
| Document: 0001104659-26-060726-index.html | 0001104659-26-060726 |
| Document: 0001104659-26-060726.txt | 0001104659-26-060726 |
| 8-K Data (Synthetic) | 0001104659-26-060726 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 144 | $10.82 | awaiting T+60 | — | $9.18 (−15.16%) |
Sep 24, 2026 4w ago | 3 | $10.91 | awaiting T+60 | — | $9.18 (−15.86%) |
Sep 23, 2026 4w ago | 8-K | $11.75 | awaiting T+60 | — | $9.18 (−21.87%) |
Aug 18, 2026 9w ago | 144 | $14.97 | awaiting T+60 | — | $9.18 (−38.68%) |
Aug 13, 2026 10w ago | 8-K | $12.67 | awaiting T+60 | — | $9.18 (−27.55%) |
Aug 13, 2026 10w ago | Press Release | $12.67 | awaiting T+60 | — | $9.18 (−27.55%) |
Jul 7, 2026 15w ago | 8-K | $14.66 $11.00 | ▼ −24.97% | ▼ −26.96% | $9.18 (−37.38%) |
May 19, 2026 22w ago | 144 | $9.58 $13.52 | ▲ +41.13% | ▲ +36.12% | $9.18 (−4.18%) |
May 14, 2026 23w ago | 8-K | $9.95 $13.02 | ▲ +30.85% | ▲ +27.27% | $9.18 (−7.74%) |
May 14, 2026 23w ago | Press Release | $9.95 $13.02 | ▲ +30.85% | ▲ +27.27% | $9.18 (−7.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers